Precipio Inc
NASDAQ:PRPO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Precipio Inc
Cash Taxes Paid
Precipio Inc
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Precipio Inc
NASDAQ:PRPO
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash Taxes Paid
$173m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-5%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash Taxes Paid
-$2.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Cigna Corp
NYSE:CI
|
Cash Taxes Paid
$399m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-10%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash Taxes Paid
$171.1m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-4%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Cash Taxes Paid
$869k
|
CAGR 3-Years
-13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Precipio Inc
Glance View
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
